Bridge Biotherapeutics announced on the 15th that it will present preclinical research results of its 4th-generation lung cancer targeted therapy candidate 'BBT-207' in a poster session at the AACR Annual Meeting 2023, held next month in Orlando, Florida, USA.
According to the abstract released on the conference website the previous day (local time), Bridge Biotherapeutics will present data on the antitumor efficacy of BBT-207 confirmed through preclinical studies, as well as its potential to inhibit brain metastasis.
BBT-207 is the first new drug candidate discovered independently by Bridge Biotherapeutics. It is a novel EGFR tyrosine kinase inhibitor (TKI) that targets resistance mutations that may arise after treatment with 3rd-generation epidermal growth factor receptor (EGFR) inhibitors such as Tagrisso (active ingredient osimertinib).
Last year at AACR, the company also presented preclinical data of BBT-207 in a poster session, revealing the pharmacokinetic properties of the drug explored through cell line and animal experiments, along with its inhibitory effects on C797S-positive double mutations and various resistance mutations. At this year's meeting, based on additional animal study results, the company will present data related to the potential for targeted therapy against C797S-positive mutations, including ▲antitumor efficacy ▲improved survival in brain metastasis animal models ▲and brain metastasis inhibition capabilities.
Jimmy Jin, Vice President in charge of discovery biology at Bridge Biotherapeutics, said, “Following the major preclinical data revealed at the global conference last year, we are pleased to present again this year the excellent antitumor efficacy of BBT-207 and improved survival results in brain metastasis models,” adding, “We have observed promising potential for BBT-207 as a 4th-generation targeted therapy for lung cancer.”
The company believes that as Tagrisso expands its role as a first-line treatment for non-small cell lung cancer, the need for new treatment options targeting various mutations, including C797S-positive double mutations, is increasing. Accordingly, BBT-207 is being developed as a 4th-generation therapy capable of addressing these C797S-positive double mutations and other resistance mutations. The company aims to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the first half of this year.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
